Analyst Price Targets — CGEN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 7, 2026 11:08 am | — | H.C. Wainwright | $4.00 | $1.55 | TheFly | Compugen initiated with a Buy at H.C. Wainwright |
| May 21, 2024 7:48 am | Asthika Goonewardene | Truist Financial | $4.00 | $1.74 | TheFly | Compugen price target lowered to $4 from $5 at Truist |
| May 20, 2024 3:43 pm | Stephen Willey | Stifel Nicolaus | $4.00 | $1.74 | StreetInsider | Stifel Reiterates Buy Rating on Compugen (CGEN) |
| May 20, 2024 1:21 pm | Asthika Goonewardene | Truist Financial | $5.00 | $1.74 | StreetInsider | Compugen (CGEN) PT Raised to $5 at Truist Securities |
Latest News for CGEN
HOLON, Israel, April 9, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will present at the 25th Annual Needham Virtual Healthcare Conference.
Compugen (NASDAQ: CGEN) executives used the company's fourth-quarter and full-year 2025 earnings call to highlight a strengthened balance sheet following a non-dilutive transaction with AstraZeneca, clinical progress across its wholly owned and partnered oncology programs, and strategic priorities that center on advancing its COM-701 ovarian cancer study and supporting Gilead-partnered GS-0321 development.…
Compugen remains a 'Buy,' supported by pipeline progress, major pharma partnerships, and a cash runway extended into 2029. Key catalysts include the phase 3 MAIA-Ovarian cancer trial (COM701), with interim analysis expected in Q1 2027, and the anti-IL18BP antibody GS-0321 in phase 1. CGEN's non-dilutive deal with AstraZeneca monetizes rilvegostomig royalties, enhancing financial stability and preserving future…
Compugen Ltd. (CGEN) Q4 2025 Earnings Call Transcript
Compugen (CGEN) came out with quarterly earnings of $0.6 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to a loss of $0.07 per share a year ago.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CGEN.
U.S. House Trading
No House trades found for CGEN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.